Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Increased Glycation Ratio and Risk of Complications in Latent Autoimmune Diabetes in Adults Compared With Type 1 Diabetes Onset before 30 Years: A Cohort Study.

Diabetes technology & therapeutics·2026
Same author

Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC.

Frontiers in artificial intelligence·2026
Same author

First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine·2026
Same author

Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

What Is the Acheulean?

Evolutionary anthropology·2026

Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Emerging Targeted Therapies for HER2-Mutant NSCLC.

Benedetta Del Rio1, Silvia Masini2, Camilo Cáceres-Galvis3

  • 1Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|May 4, 2026
PubMed
Summary
This summary is machine-generated.

HER2-mutant lung cancer (NSCLC) shows poor prognosis, but targeted therapies like antibody-drug conjugates and tyrosine-kinase inhibitors offer effective treatment options. Novel TKIs demonstrate deep responses with improved tolerability and lower interstitial lung disease risk.

Keywords:
Antibody-drug conjugatesHER2HER2-mutant NSCLCHER2-selective tyrosine kinase inhibitors

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

Related Experiment Videos

Last Updated: May 6, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2-mutant non-small cell lung cancer (NSCLC) is rare (2-5%) and linked to poor outcomes.
  • Existing HER2-targeted therapies, including antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd), show efficacy but carry risks like interstitial lung disease (ILD).

Purpose of the Study:

  • To review the molecular landscape and clinical features of HER2-mutant NSCLC.
  • To summarize evidence for HER2-targeted therapies in NSCLC.
  • To provide a future outlook on treatment strategies for HER2-mutant NSCLC.

Main Methods:

  • Literature review of clinical trials and preclinical studies on HER2-targeted therapies for NSCLC.
  • Analysis of efficacy and toxicity profiles of approved and investigational agents.
  • Discussion of molecular characteristics and clinical presentation of HER2-mutant NSCLC.

Main Results:

  • Trastuzumab deruxtecan (T-DXd) is an approved ADC for HER2-mutant NSCLC, achieving ~50% response rates but with a risk of ILD.
  • Novel HER2-selective tyrosine kinase inhibitors (TKIs), such as sevabertinib and zongertinib, demonstrate deep and durable responses.
  • TKIs exhibit improved safety profiles, with lower rates of ILD and toxicities mainly related to wild-type EGFR inhibition, particularly zongertinib.

Conclusions:

  • HER2-mutant NSCLC treatment is evolving with effective targeted therapies.
  • ADCs and TKIs offer distinct mechanisms and efficacy in HER2-mutant NSCLC.
  • Novel HER2-targeted TKIs present a promising therapeutic avenue with favorable tolerability, potentially improving outcomes for NSCLC patients.